JP2013503901A5 - - Google Patents

Download PDF

Info

Publication number
JP2013503901A5
JP2013503901A5 JP2012528084A JP2012528084A JP2013503901A5 JP 2013503901 A5 JP2013503901 A5 JP 2013503901A5 JP 2012528084 A JP2012528084 A JP 2012528084A JP 2012528084 A JP2012528084 A JP 2012528084A JP 2013503901 A5 JP2013503901 A5 JP 2013503901A5
Authority
JP
Japan
Prior art keywords
group
amino
pyridin
methyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012528084A
Other languages
English (en)
Japanese (ja)
Other versions
JP5868855B2 (ja
JP2013503901A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/047800 external-priority patent/WO2011028995A1/en
Publication of JP2013503901A publication Critical patent/JP2013503901A/ja
Publication of JP2013503901A5 publication Critical patent/JP2013503901A5/ja
Application granted granted Critical
Publication of JP5868855B2 publication Critical patent/JP5868855B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012528084A 2009-09-03 2010-09-03 チロシンキナーゼ調節剤としての化合物 Expired - Fee Related JP5868855B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US23960309P 2009-09-03 2009-09-03
US61/239,603 2009-09-03
US30661610P 2010-02-22 2010-02-22
US61/306,616 2010-02-22
US35669910P 2010-06-21 2010-06-21
US61/356,699 2010-06-21
US36053110P 2010-07-01 2010-07-01
US61/360,531 2010-07-01
PCT/US2010/047800 WO2011028995A1 (en) 2009-09-03 2010-09-03 Compounds as tyrosine kinase modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016001387A Division JP6109974B2 (ja) 2009-09-03 2016-01-06 チロシンキナーゼ調節剤としての化合物

Publications (3)

Publication Number Publication Date
JP2013503901A JP2013503901A (ja) 2013-02-04
JP2013503901A5 true JP2013503901A5 (enExample) 2013-10-24
JP5868855B2 JP5868855B2 (ja) 2016-02-24

Family

ID=43086186

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012528084A Expired - Fee Related JP5868855B2 (ja) 2009-09-03 2010-09-03 チロシンキナーゼ調節剤としての化合物
JP2012528089A Pending JP2013503903A (ja) 2009-09-03 2010-09-03 チロシンキナーゼモジュレーターとしての化合物
JP2016001387A Expired - Fee Related JP6109974B2 (ja) 2009-09-03 2016-01-06 チロシンキナーゼ調節剤としての化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012528089A Pending JP2013503903A (ja) 2009-09-03 2010-09-03 チロシンキナーゼモジュレーターとしての化合物
JP2016001387A Expired - Fee Related JP6109974B2 (ja) 2009-09-03 2016-01-06 チロシンキナーゼ調節剤としての化合物

Country Status (19)

Country Link
US (5) US8614234B2 (enExample)
EP (2) EP2473513B1 (enExample)
JP (3) JP5868855B2 (enExample)
KR (2) KR20120047313A (enExample)
CN (2) CN102498114A (enExample)
AU (2) AU2010289353B2 (enExample)
BR (2) BR112012004843A2 (enExample)
CA (2) CA2772718C (enExample)
CL (2) CL2012000592A1 (enExample)
ES (1) ES2730086T3 (enExample)
IL (2) IL218332A0 (enExample)
IN (1) IN2012DN02493A (enExample)
MX (2) MX2012002596A (enExample)
NZ (2) NZ598455A (enExample)
PH (1) PH12014500281A1 (enExample)
RU (2) RU2012109233A (enExample)
SG (2) SG178965A1 (enExample)
WO (2) WO2011029001A1 (enExample)
ZA (2) ZA201201592B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9902709B2 (en) 2014-04-08 2018-02-27 Peking University Founder Group Co., Ltd. Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
BRPI0914772A2 (pt) 2008-06-25 2015-10-20 Envivo Pharmaceuticals Inc compostos heterocíclicos 1,2-dissubstituídos
CA2740746A1 (en) 2008-10-14 2010-04-22 Ning Xi Compounds comprising a spiro-ring and and methods of use
EP2408300B1 (en) 2009-03-21 2016-05-11 Sunshine Lake Pharma Co., Ltd. Amino ester derivatives, salts thereof and methods of use
CA2761032A1 (en) * 2009-05-07 2010-11-11 Envivo Pharmaceuticals, Inc. Phenoxymethyl heterocyclic compounds
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 薬剤溶出眼内インプラント
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US8906944B2 (en) * 2009-09-03 2014-12-09 Allergan, Inc. Compounds as tyrosine kinase modulators
US8614234B2 (en) * 2009-09-03 2013-12-24 Allergan, Inc. Compounds as tyrosine kinase modulators
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
SG11201404630UA (en) * 2012-02-09 2014-09-26 Merck Patent Gmbh Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as tbk1 and ikk inhibitors
WO2015069287A1 (en) * 2013-11-08 2015-05-14 Allergan, Inc. Compounds as tyrosine kinase modulators
JP6878004B2 (ja) 2013-12-13 2021-05-26 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
JP6879740B2 (ja) * 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
US20150342875A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
CN104326985A (zh) * 2014-09-24 2015-02-04 安润医药科技（苏州）有限公司 利你法尼的制备方法
US10112957B2 (en) 2014-10-22 2018-10-30 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
WO2017157332A1 (zh) * 2016-03-18 2017-09-21 江苏恒瑞医药股份有限公司 芳香酰胺类衍生物、其制备方法及其在医药上的应用
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
CN107663202B (zh) * 2016-07-29 2020-09-04 西华大学 3-(脲基-甲基)-4-芳基-吡啶衍生物及其制备方法和作为抗肝癌药物的应用
EP3600333A4 (en) 2017-03-21 2020-11-25 The Scripps Research Institute CU AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS
RS62430B1 (sr) 2017-05-11 2021-11-30 Bristol Myers Squibb Co Tienopiridini i benzotiofeni korisni kao irak4 inhibitori
CN110770210A (zh) * 2017-05-18 2020-02-07 Pi工业有限公司 新颖的脒化合物
PT3860998T (pt) 2018-10-05 2024-04-02 Annapurna Bio Inc Compostos e composições para o tratamento de condições associadas à atividade do recetor apj
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
WO1991015495A1 (en) 1990-04-02 1991-10-17 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
CA2108889A1 (en) 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
CA2140440A1 (en) 1992-08-06 1994-02-17 Ellen M. Dobrusin 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1999020617A1 (en) * 1997-10-21 1999-04-29 Active Biotech Ab Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors
EP1415987B1 (en) * 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
IL158783A0 (en) * 2001-05-08 2004-05-12 Schering Ag Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
US20030225152A1 (en) 2001-09-27 2003-12-04 Andrews Steven W. 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US6541504B1 (en) 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
TWI319387B (en) * 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US20050058689A1 (en) 2003-07-03 2005-03-17 Reactive Surfaces, Ltd. Antifungal paints and coatings
US6747025B1 (en) 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
CA2516627A1 (en) * 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Substituted pyridine derivatives useful in the treatment of cancer and other disorders
DE602004007382T2 (de) * 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
CA2536321A1 (en) * 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
CA2536788A1 (en) * 2003-08-29 2005-03-10 Pfizer Inc. Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
JP2007537296A (ja) * 2004-05-14 2007-12-20 アボット・ラボラトリーズ 治療薬としてのキナーゼ阻害薬
MX2007007574A (es) * 2004-12-22 2007-07-24 Astrazeneca Ab Derivados de piridina-carboxamida para uso como agentes anticancerosos.
US8518950B2 (en) 2005-01-25 2013-08-27 Synta Pharmaceuticals Corp. 2-amido pyrazines for inflammation and immune related uses
WO2006081389A1 (en) * 2005-01-25 2006-08-03 Synta Pharmaceuticals Corp. Thiophene compounds for inflammation and immune-related uses
MX2007011234A (es) * 2005-03-14 2007-11-12 Transtech Pharma Inc Derivados de benzazol, composiciones y metodos de uso en la forma de inhibidores de b-secretasa.
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
ES2473341T3 (es) 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
JP2008545756A (ja) * 2005-06-03 2008-12-18 バイエル・ヘルスケア・アクチェンゲゼルシャフト 癌化学療法剤として有用な１−メチル−１ｈ−ピラゾール−４−カルボキサミド類
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
WO2007076474A1 (en) * 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
AR059246A1 (es) 2006-01-30 2008-03-19 Array Biopharma Inc Compuestos heterobiciclicos de tiofeno y metodos de uso
WO2007107005A1 (en) 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
WO2007111904A2 (en) * 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
US7790756B2 (en) * 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
CA2684950A1 (en) * 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
MX2009011754A (es) * 2007-04-30 2009-12-01 Abbott Lab Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
EP2183254B1 (en) * 2007-08-29 2017-06-21 MethylGene Inc. Inhibitors of protein tyrosine kinase activity
US20090118276A1 (en) * 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
WO2009070328A1 (en) 2007-11-26 2009-06-04 The Regents Of The University Of California Modulators of the epidermal growth factor receptor (egfr) pathway for use in the treatment or prevention of substance abuse
US20100324086A1 (en) * 2008-02-19 2010-12-23 Novasaid Ab Compounds and methods
WO2009109035A1 (en) * 2008-03-05 2009-09-11 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
EP2331530B8 (en) * 2008-09-26 2013-12-25 National Health Research Institutes Fused multicyclic compounds as protein kinase inhibitors
US8906944B2 (en) * 2009-09-03 2014-12-09 Allergan, Inc. Compounds as tyrosine kinase modulators
US8614234B2 (en) 2009-09-03 2013-12-24 Allergan, Inc. Compounds as tyrosine kinase modulators

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9902709B2 (en) 2014-04-08 2018-02-27 Peking University Founder Group Co., Ltd. Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition

Similar Documents

Publication Publication Date Title
RU2012112151A (ru) Соединения как модуляторы тирозинкиназы
RU2482111C2 (ru) Соединения, обладающие противораковой активностью
RU2497813C2 (ru) 4-(4-циано-2-тиоарил)-дигидропиримидиноны и их применение
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
RU2454405C2 (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
JP2010508338A5 (enExample)
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2013503903A5 (enExample)
RU2451674C2 (ru) Пиридинкарбоксамиды в качестве ингибиторов 11-бета-hsd1
JP2013517283A5 (enExample)
JP2007519754A5 (enExample)
JP2014511869A5 (enExample)
JP2006500348A5 (enExample)
RU2014142598A (ru) Новые 4-метилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
JP2005511543A5 (enExample)
RU2015133171A (ru) Бензиламиновые производные
JP2017522374A5 (enExample)
CA2550596A1 (en) 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
JP2019537603A5 (enExample)
JP2019505595A5 (enExample)
RU2009149497A (ru) Фунгицид на основе гетероциклил-пиримидинил-аминопроизводных
RU2013123057A (ru) N-бензил гетероциклические карбоксамиды
RU2010138577A (ru) ИНГИБИТОРЫ РЕЦЕПТОРА ХЕМОКИНА CxCR3
JP2010523644A5 (enExample)
JP2018515489A5 (enExample)